SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (152)9/27/2000 11:35:21 AM
From: scaram(o)uche  Read Replies (1) of 724
 
I'm not really concerned with "effect". I'm more interested with "intent". I suspect that, when the dust settles, DGI will no longer be a subsidiary of NBSC.

I continue to value the patent claim at $40 million. The "antibody" can be agonist or antagonist. The small molecule can be agonist or antagonist.

Anybody with half a brain can turn the existing patent, the pIgR application, the Novo agreement, and the disclosures at the DGI site into big bucks.

I have a terrible feeling -- and I've had it for some time -- that NBS is going to turn big bucks into 50% of big bucks.

That will be good enough.

As a contributor at Yahoo noted.... the parent company, in this environment, should be PRINTING money.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News